Erratum: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2013) 24 (vi24-vi32) DOI: 10.1093/annonc/mdt333);Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages iv259-

  Ledermann, J A ^a   Raja, F A ^a   Fotopoulou, C ^b   Gonzalez Martin, A ^c   Colombo, N ^d   Sessa, C ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MD ANDERSON CANCER CENTER   (Spain)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN; TRABECTEDIN;

ADVANCED CANCER; ALLERGIC REACTION; ALLERGY; ALOPECIA; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CYTOREDUCTIVE SURGERY; DRUG DOSE COMPARISON; FOLLOW UP; HUMAN; LAPAROTOMY; LYMPH NODE DISSECTION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVARY CARCINOMA; PERSONALIZED MEDICINE; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY; TREATMENT PLANNING; TREATMENT RESPONSE;

AGE FACTORS; AGING; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; CHEMOTHERAPY, ADJUVANT; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84885334240     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy157     Document Type: Erratum

References (58)

1. EUCAN Cancer Factsheets: Ovary. http://eu-cancer.iarc.fr/EUCAN/CancerOne.aspx?Cancer=27&Gender=2 (11 July 2013, date last accessed).
2. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2009 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute 2013. http://www.cdc.gov/uscs (11 July 2013, date last accessed).
3. Alsop K, Fereday S, Meldrum C et al. BRCA Mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-2663.
4. Scully RE, Sobin LH, Serov SF. Histological Typing of Ovarian Tumours. Berlin, Heidelberg, New York: Springer 1999.
5. Mackay HJ, Brady MF, Oza AM et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952.
6. Shimizu Y, Kamoi S, Amada S et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82: 893-901.
7. Bodurka DC, Deavers MT, Tian C et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 2012; 118: 3087-3094.
8. Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-282.
9. Bonome T, Lee JY, Park DC et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65: 10602-10612.
10. Diaz-Padilla I, Malpica AL, Minig L et al. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012; 126: 279-285.
11. Schmeler KM, Sun CC, Bodurka DC et al. Neoadjuvant chemotherapy for lowgrade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008; 108: 510-514.
12. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
13. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011; 43: 420-432.
14. Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
15. Vang R, Shih I-M, Kurman RJ. Fallopian tube precursors of ovarian low- and highgrade serous neoplasms. Histopathology 2013; 62: 44-58.
16. Carlson JW, Miron A, Jarboe EA et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008; 26: 4160-4165.
17. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994; 170: 81-85.
18. Garcia-Soto AE, Boren T, Wingo SN et al. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol 2012; 206: 242.e241-242.e245.
19. Timmers PJ, Zwinderman AH, Coens C et al. Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer 2010; 46: 880-884;
20. Cass I, Li AJ, Runowicz CD et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001; 80: 56-61.
21. Maggioni A, Benedetti Panici P, Dell'Anna T et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006; 95: 699-704.
22. Fruscio R, Corso S, Ceppi L et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 2013; 24: 138-144.
23. du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009; 115: 1234-1244.
24. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-634.
25. Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953.
26. Aletti GD, Dowdy SC, Gostout BS et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg 2009; 208: 614-620.
27. du Bois A, Reuss A, Harter P et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010; 28: 1733-1739.
28. Panici PB, Maggioni A, Hacker N et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97: 560-566.
29. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 351: 2489-2497.
30. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009; 16: 1324-1330.
31. Zang RY, Harter P, Chi DS et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 2011; 105: 890-896.
32. Fotopoulou C, Zang R, Gultekin M et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol 2013; 20: 1348-1354.
33. Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant ( post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 2009; CD004706.
34. Swart AC, on behalf of ICON Collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol (Meeting Abstracts) 2007; 25(18 suppl): Abstr 5509.
35. Chan JK, Tian C, Fleming GF et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116: 301-306.
36. du Bois A, Lueck H, Meier W et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an AGO trial. Proc Am Soc Clin Oncol 1999; 18: 356a (abstr 1374).
37. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-3092.
38. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200.
39. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-1425.
40. Pignata S, Scambia G, Ferrandina G et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011; 29: 3628-3635.
41. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
42. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
43. Hess LM, Benham-Hutchins M, Herzog TJ et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007; 17: 561-570.
44. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
45. Katsumata N, Yasuda M, Isonishi S et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol 2012; 30 (suppl): abstr 5003.
46. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365: 2473-2483.
47. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
48. Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21: 419-423.
49. Friedlander M, Trimble E, Tinker A et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21: 771-775.
50. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
51. Raja FA, Counsell N, Colombo N et al. Platinum combination chemotherapy versus platinum monotherapy in platinum-sensitive recurrent ovarian cancer: a metaanalysis of randomised trials using individual patients data (IPD). Ann Oncol 2012; 23: abstr 982P.
52. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329.
53. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
54. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinumsensitive ( platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22: 39-48.
55. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045.
56. Pujade Lauraine E, Hilpert F, Weber B et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012; 30(suppl): abstr LBA5002.
57. Rustin GJ, van der Burg ME, on behalf of MRC and EORTC collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol (Meeting Abstracts) 2009; 27(18s): 1.
58. Heintz APM, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. Int J Gynecol Obstet 2006; 95(suppl 1): S163.